71 related articles for article (PubMed ID: 15907712)
21. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
[TBL] [Abstract][Full Text] [Related]
22. A Phase II study of oxaliplatin in urothelial cancer.
Winquist E; Vokes E; Moore MJ; Schumm LP; Hoving K; Stadler WM
Urol Oncol; 2005; 23(3):150-4. PubMed ID: 15907713
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
Toppmeyer D; Seidman AD; Pollak M; Russell C; Tkaczuk K; Verma S; Overmoyer B; Garg V; Ette E; Harding MW; Demetri GD
Clin Cancer Res; 2002 Mar; 8(3):670-8. PubMed ID: 11895894
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
[TBL] [Abstract][Full Text] [Related]
25. [Combination chemotherapy of advanced transitional cell carcinoma with cis-platinum, cyclophosphamide, adriamycin and 5-fluorouracil (CISCAF)].
Fujioka H; Tada Y; Nakano E; Matsuda M; Osafune M; Sagawa S; Takaha M; Sonoda T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1612-6. PubMed ID: 6541019
[TBL] [Abstract][Full Text] [Related]
26. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma.
Rink M; Robinson BD; Green DA; Cha EK; Hansen J; Comploj E; Margulis V; Raman JD; Ng CK; Remzi M; Bensalah K; Kabbani W; Haitel A; Rioux-Leclercq N; Guo CC; Chun FK; Kikuchi E; Kassouf W; Sircar K; Sun M; Sonpavde G; Lotan Y; Pycha A; Karakiewicz PI; Scherr DS; Shariat SF
J Urol; 2012 Aug; 188(2):398-404. PubMed ID: 22698626
[TBL] [Abstract][Full Text] [Related]
27. A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract.
Stewart GD; Bariol SV; Grigor KM; Tolley DA; McNeill SA
BJU Int; 2005 Apr; 95(6):791-3. PubMed ID: 15794784
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder.
Khorsand M; Lange J; Feun L; Clendeninn NJ; Collier M; Wilding G
Invest New Drugs; 1997; 15(2):157-63. PubMed ID: 9220296
[TBL] [Abstract][Full Text] [Related]
29. Bladder tumor recurrence after primary surgery for transitional cell carcinoma of the upper urinary tract.
Oehlschläger S; Baldauf A; Wiessner D; Gellrich J; Hakenberg OW; Wirth MP
Urol Int; 2004; 73(3):209-11. PubMed ID: 15539838
[TBL] [Abstract][Full Text] [Related]
30. The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.
Bachmann HS; Meier W; du Bois A; Kimmig R; Kuhlmann JD; Siffert W; Sehouli J; Wollschlaeger K; Huober J; Hillemanns P; Burges A; Schmalfeldt B; Aminossadati B; Wimberger P
Br J Clin Pharmacol; 2015 Nov; 80(5):1139-48. PubMed ID: 26033044
[TBL] [Abstract][Full Text] [Related]
31. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.
Sharma S; Kemeny N; Kelsen DP; Ilson D; O'Reilly E; Zaknoen S; Baum C; Statkevich P; Hollywood E; Zhu Y; Saltz LB
Ann Oncol; 2002 Jul; 13(7):1067-71. PubMed ID: 12176785
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium.
Dumez H; Gallardo E; Culine S; Galceran JC; Schöffski P; Droz JP; Extremera S; Szyldergemajn S; Fléchon A
Mar Drugs; 2009 Sep; 7(3):451-63. PubMed ID: 19841725
[TBL] [Abstract][Full Text] [Related]
33. Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.
Kauh J; Chanel-Vos C; Escuin D; Fanucchi MP; Harvey RD; Saba N; Shin DM; Gal A; Pan L; Kutner M; Ramalingam SS; Bender L; Marcus A; Giannakakou P; Khuri FR
Cancer; 2011 Sep; 117(17):4049-59. PubMed ID: 21365629
[TBL] [Abstract][Full Text] [Related]
34. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Feldman EJ; Cortes J; DeAngelo DJ; Holyoake T; Simonsson B; O'Brien SG; Reiffers J; Turner AR; Roboz GJ; Lipton JH; Maloisel F; Colombat P; Martinelli G; Nielsen JL; Petersdorf S; Guilhot F; Barker J; Kirschmeier P; Frank E; Statkevich P; Zhu Y; Loechner S; List A
Leukemia; 2008 Sep; 22(9):1707-11. PubMed ID: 18548095
[TBL] [Abstract][Full Text] [Related]
35. [Neoadjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma: current evidence].
Bolenz C; Zengerling F
Urologie; 2023 May; 62(5):522-524. PubMed ID: 37076603
[No Abstract] [Full Text] [Related]
36. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Malig Rep; 2006 Mar; 1(1):20-4. PubMed ID: 20425327
[TBL] [Abstract][Full Text] [Related]
37. Lonafarnib for cancer and progeria.
Wong NS; Morse MA
Expert Opin Investig Drugs; 2012 Jul; 21(7):1043-55. PubMed ID: 22620979
[TBL] [Abstract][Full Text] [Related]
38. Doxorubicin chemotherapy in advanced transitional cell carcinoma.
Weinstein SH; Schmidt JD
Urology; 1976 Oct; 8(4):336-41. PubMed ID: 973286
[TBL] [Abstract][Full Text] [Related]
39. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma.
Andreev-Drakhlin A; Gao J; Siefker-Radtke A
Eur Urol; 2021 May; 79(5):655-656. PubMed ID: 32921520
[No Abstract] [Full Text] [Related]
40. The prenylation inhibitor, lonafarnib: a new therapeutic strategy against hepatitis delta.
Rizzetto M; Ciancio A
Lancet Infect Dis; 2015 Oct; 15(10):1119-1120. PubMed ID: 26189435
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
